Strategic Initiative

Slingshot members are tracking this corporate initiative:

AstraZeneca (AZN) strikes collaboration worth $6.9B to sell and develop Daiichi Sankyo's (DSNKY) HER2-targeting antibody-drug conjugate, Trastuzumab deruxtecan

Source Link:: https://www.astrazeneca.com/media-centre/press-releases/2019/astrazeneca-and-daiichi-sankyo-enter-collaboration-for-novel-her-2-targeting-antibody-drug-conjugate.html

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

AZN

100%

DSNKY

100%

SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details
Shares in Daiichi surged 16% in Tokyo on news of the deal, which AstraZeneca will partly fund through a $3.5B share sale and $1.35B upfront payment.

https://seekingalpha...

Slingshot Insights Explained

JOIN FOR FREE TODAY

Strategic Initiative Date

Announcement Date:

Mar 29, 2019

Projected Implementation:

Q1, 2019

Relevance Tracked Until:

Q3, 2019

Related Projects

Don’t see a project related to the strategic initiative you care about?

Related Keywords Trastuzumab Deruxtecan, Her2